Exelixis, Inc. $EXEL Shares Purchased by Cetera Investment Advisers

Posted by Francis Steltz on Aug 2nd, 2026

Cetera Investment Advisers increased its position in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 17.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 169,881 shares of the biotechnology company’s stock after acquiring an additional 25,187 shares during the period. Cetera Investment Advisers’ holdings in Exelixis were worth $7,286,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in EXEL. AQR Capital Management LLC increased its holdings in shares of Exelixis by 48.8% in the fourth quarter. AQR Capital Management LLC now owns 13,658,388 shares of the biotechnology company’s stock valued at $598,647,000 after purchasing an additional 4,477,029 shares during the period. Invesco Ltd. lifted its holdings in shares of Exelixis by 1.6% during the fourth quarter. Invesco Ltd. now owns 6,054,743 shares of the biotechnology company’s stock worth $265,379,000 after purchasing an additional 94,218 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Exelixis by 0.9% during the first quarter. Dimensional Fund Advisors LP now owns 4,299,597 shares of the biotechnology company’s stock worth $184,391,000 after purchasing an additional 39,920 shares during the period. Morgan Stanley lifted its holdings in shares of Exelixis by 31.0% during the fourth quarter. Morgan Stanley now owns 4,206,656 shares of the biotechnology company’s stock worth $184,378,000 after purchasing an additional 995,949 shares during the period. Finally, UBS Group AG boosted its position in Exelixis by 40.2% in the fourth quarter. UBS Group AG now owns 3,722,334 shares of the biotechnology company’s stock valued at $163,150,000 after buying an additional 1,067,265 shares during the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Insiders Place Their Bets

In other Exelixis news, CFO Christopher J. Senner sold 34,901 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $50.00, for a total value of $1,745,050.00. Following the sale, the chief financial officer owned 952,317 shares in the company, valued at approximately $47,615,850. This represents a 3.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Jack L. Wyszomierski sold 3,925 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $50.55, for a total transaction of $198,408.75. Following the sale, the director directly owned 284,384 shares in the company, valued at $14,375,611.20. The trade was a 1.36% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 219,170 shares of company stock worth $10,620,641. Corporate insiders own 2.60% of the company’s stock.

Exelixis Stock Down 5.3%

Shares of EXEL stock opened at $53.03 on Friday. Exelixis, Inc. has a 52-week low of $33.76 and a 52-week high of $57.57. The stock has a market cap of $13.33 billion, a PE ratio of 17.62, a price-to-earnings-growth ratio of 1.53 and a beta of 0.42. The business has a 50-day simple moving average of $53.73 and a 200-day simple moving average of $47.58.

Exelixis (NASDAQ:EXEL – Get Free Report) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.75 by $0.12. The firm had revenue of $610.81 million for the quarter, compared to analyst estimates of $607.51 million. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.Exelixis’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same period last year, the company earned $0.55 earnings per share. Sell-side analysts anticipate that Exelixis, Inc. will post 3.15 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. UBS Group reiterated a “buy” rating on shares of Exelixis in a report on Thursday, July 2nd. HC Wainwright restated a “buy” rating and set a $56.00 price objective on shares of Exelixis in a research note on Thursday, July 2nd. Wall Street Zen raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Weiss Ratings lowered shares of Exelixis from a “buy (b+)” rating to a “buy (b)” rating in a research note on Friday, July 24th. Finally, TD Cowen increased their price objective on shares of Exelixis from $51.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Eight equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Exelixis presently has an average rating of “Hold” and a consensus price target of $49.29.

Check Out Our Latest Report on EXEL

Exelixis Company Profile

(Free Report)

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.